NRAS and melanoma: To highlight the utility of our platform, we generated substitution mutations in each exon of three human genes (MAP2K1, KRAS, NRAS) associated with resistance to vemurafenib19,20, which is a cancer drug targeting the BRAF V600E mutation in melanoma patients.